Topic Menu
► Topic MenuTopic Editors
Cancer Stem Cells, DNA Methylation and DNA Sequences: Their Diagnostic and Therapeutical Applications
Topic Information
Dear Colleagues,
DNA methylation is an essential epigenetic mechanism for controlling gene expression in both embryonic and adult stem cells. There is a fine-tuned balance between the regulation of gene activation and repression during normal cellular activity, and either hypo- or hypermethylation could induce the expression or inhibition of genes, respectively. Changes in methylation status are acknowledged to be hallmarks for cancer initiation and progression, with the potential to transform normal stem cells into a cancer stem cell (CSC) phenotype. The basic function of the immune system is to provide the host with protection from invading foreign antigens in parallel with the state of self-tolerance, i.e., maintaining its unique antigenic profile. Cellular structures such as nuclei and mitochondria house the vast bulk of DNA. Changes in DNA sequences have gained attention as potential biomarkers since they can be detected as extracellular cell-free DNA (cfDNA) in a wide range of diseases, including cancer. Recently, cfDNA testing has seen a resurgence due to the widespread use of liquid biopsies and the growing need for disease screening, activity monitoring, and drug response assessments. Studies on the immunological effects of cfDNA, in addition to their immunomodulatory or therapeutic advantages, are still in their infancy. The main aim of this Special Issue (Topic) is to discuss the impact of aberrant DNA methylation statuses on CSC functions, including self-renewal, differentiation, drug resistance, and metastasis formation, in addition to analyzing recent findings on the role of different DNA-sensing receptors in the recognition of foreign or self-DNA sequences as potent danger-associated molecular patterns. Further, emphasizing the immunomodulatory as well as pro- and anti-tumor capacities of different DNA sequences, and thus their subsequent potential for anticancer therapy, this Special Issue (Topic) also intends to summarize the results of recent experimental studies.
Dr. Ferenc Sipos
Dr. Györgyi Műzes
Topic Editors
Keywords
- cancer stem cells
- DNA methylation
- epigenome
- drug resistance
- metastasis
- self-renewal
- hypermethylation
- hypomethylation
- DNA sequence
- cell-free DNA
- DNA sensing
- methylation signatures
- differentially methylated probes or regions
- diagnostic performance
- therapy
- liquid biopsy
- DNA methylation technologies
- tissue of origin (TOO)
- CpG oligonucleotides
- toll-like receptor 9
- absent in melanoma-2
- cyclic GMP–AMP synthase
- tumor microenvironment
Participating Journals
Journal Name | Impact Factor | CiteScore | Launched Year | First Decision (median) | APC | |
---|---|---|---|---|---|---|
Biomedicines
|
3.9 | 5.2 | 2013 | 15.3 Days | CHF 2600 | Submit |
Cancers
|
4.5 | 8.0 | 2009 | 16.3 Days | CHF 2900 | Submit |
Cells
|
5.1 | 9.9 | 2012 | 17.5 Days | CHF 2700 | Submit |
Journal of Clinical Medicine
|
3.0 | 5.7 | 2012 | 17.3 Days | CHF 2600 | Submit |
Pharmaceutics
|
4.9 | 7.9 | 2009 | 14.9 Days | CHF 2900 | Submit |
Reports
|
0.8 | - | 2018 | 18.4 Days | CHF 1400 | Submit |
Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.
MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:
- Immediately share your ideas ahead of publication and establish your research priority;
- Protect your idea from being stolen with this time-stamped preprint article;
- Enhance the exposure and impact of your research;
- Receive feedback from your peers in advance;
- Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.